OS Therapies Provides OST-HER2 Metastatic Osteosarcoma Program Update and Announces Upcoming Conference Attendance
Management will participate at Jefferies Global Healthcare Conference, H.C. Wainwright Global Investment Conference, ROTH Healthcare Opportunities Conference Management and business development advisors will attend BioJapan Interim 3-year overall survival data, U.S. FDA Type C Statistical Methods meeting and U.K. MHRA Statistical Methods Scientific Advice Meeting expected in September 2026 RMAT and Rolling Review decisions expected to fol
2026-09-02 7:20 AM EDT | OS Therapies
Biosenta Enters into Memorandum of Understanding with Dynamic Facility Services for TRUE(TM) Pilot Program
Calgary, Alberta--(Newsfile Corp. - September 1, 2026) - Biosenta Inc. (CSE: ZRO) ("Biosenta" or the "Company") announces that it has entered into a Memorandum of Understanding ("MOU") with Dynamic Facility Services Ltd. ("Dynamic"), a British Columbia-based commercial cleaning and facility services company, to conduct a pilot program evaluating the use of Biosenta's TRUE™ disinfectant within Dynamic's commercial cleaning operations. Under the MOU, Dynamic will conduct a pilot pro
Biotechnologies, Produits chimiques, Produits ménagers / de consommation / cosmétiques
2026-09-01 5:13 PM EDT | Biosenta Inc.
Marvel Biosciences Announces Grant of Deferred Share Units
Calgary, Alberta--(Newsfile Corp. - September 1, 2026) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), announces the award of 50,001 deferred share units ("DSUs") to Marvel's three independent directors, in lieu of cash payment for directors' fees. The DSUs will all vest on September 1, 2027. Vested DSUs shall be settled upon the directors' separation from service fr
2026-09-01 5:01 PM EDT | Marvel Biosciences Corp.
TempraMed Signs Letter of Intent with CPO Greece for Exclusive Distribution of VIVI Products in Greece
Highlights: LOI with CPO Greece includes exclusive distribution of VIVI Cap™ and VIVI Epi™ throughout Greece, subject to a definitive agreement. Proposed exclusivity is conditional on minimum annual purchase obligations, with combined purchases required to increase by at least 20% year over year to maintain exclusivity. Transfer pricing and the first-year minimum unit commitment will be negotiated an
Technologies, Biotechnologies, Pharmaceutique, Santé
2026-09-01 6:45 AM EDT | TempraMed Technologies Ltd.
Restart Life Sciences Announces Holy Crap's Amazon U.S. Rollout Alongside Next-Generation Protein and Sampling Innovations
Vancouver, British Columbia--(Newsfile Corp. - September 1, 2026) - Restart Life Sciences Corp. (CSE: HEAL) (FSE: HN30) (OTC Pink: NMLSF) ("Restart Life" or the "Company") is pleased to announce that its premium functional food brand, Holy Crap Foods Inc. ("Holy Crap"), has officially launched in the U.S. market through the Amazon USA platform. The initial U.S. rollout features two of the brand's top-performing super seed SKUs alongside a popular variety package. Following a strong ini
Technologies, Biotechnologies, Santé
2026-09-01 6:00 AM EDT | Restart Life Sciences Corp.
Defence Therapeutics Expands Radiopharmaceutical Development Strategy with Alpha and Beta-Emitter Programs
Montreal, Quebec--(Newsfile Corp. - August 31, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology company developing next-generation precision oncology therapeutics using its proprietary Accum® technology, is pleased to announce the expansion of its radiopharmaceutical development program to evaluate alpha-emitting and beta-emitting radioisotopes. This expansion is to broaden the capabi
Biotechnologies, Pharmaceutique, Santé
2026-08-31 3:15 AM EDT | Defence Therapeutics Inc.
Sharp Therapeutics Corp. Reports First Half 2026 Results and Development Update
Pennsylvania and Toronto, Ontario--(Newsfile Corp. - August 28, 2026) - Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) ("Sharp" or the "Company"), announces the release of its unaudited condensed interim consolidated financial statements for the six-month period ended June 30, 2026, and related management discussion and analysis. All dollar figures are in United States dollars, unless otherwise stated. Scott Sneddon, Sharp's Chief Executive Off
2026-08-28 5:01 PM EDT | Sharp Therapeutics Corp.
Theralase(R) Releases Q2 2026 Financial Statements
Toronto, Ontario--(Newsfile Corp. - August 28, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical-stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of various cancers, bacteria and viruses, has released the Company's unaudited interim consolidated financial statements for the six-month period ended Jun
Technologies, Biotechnologies, Soins de santé et hôpitaux, Pharmaceutique
2026-08-28 4:36 PM EDT | Theralase Technologies Inc.
MustGrow Announces Second Quarter 2026 Financial Results
Investor Webcast: Monday, August 31st at 4:00pm ET / 1:00pm PT Register/View Here: https://us02web.zoom.us/webinar/register/1317861230560/WN_oKTSGbCQR1KjX5MnyGC3kw#/registration Please join/register at least 5 minutes prior to the call. Email questions to info@mustgrow.ca before 2:00pm ET, which will be addressed during the Q&A portion of
Agriculture, Biotechnologies, Cannabis, Sélectionneurs de cannabis
2026-08-27 5:01 PM EDT | MustGrow Biologics Corp.
Moss Genomics Inc. Provides Default Status Disclosure and Update on Continuous Disclosure Review
Vancouver, British Columbia--(Newsfile Corp. - August 25, 2026) - As a result of a review by the British Columbia Securities Commission (the "BCSC"), Moss Genomics Inc. (CSE: MOSS) (FSE: F73) (OTCQB: MSSGF) (the "Company") is issuing the following news release to clarify its disclosure. The Company advises that, on July 14, 2026, it was added to the BCSC's Issuers in Default list under Canadian Securities Administrators Notice 51-322 - Reporting Issuer Defaults. The default arise
2026-08-25 9:22 AM EDT | Moss Genomics Inc.
BioMark's Metabolomics Platform Captures Global Scientific Interest Following Publications Demonstrating Superior Diagnostic Performance and Cost Efficiency for Liquid Biopsy
Vancouver, British Columbia--(Newsfile Corp. - August 25, 2026) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark" or the "Company"), a leading developer of liquid biopsy technologies focused on the early detection of lung cancer through metabolomics, is pleased to announce crucial updates reinforcing the clinical translation of its liquid biopsy technology platform for early non-small cell lung cancer (NSCLC) screening and risk stratification with the public
Technologies, Biotechnologies, Soins de santé et hôpitaux
2026-08-25 8:30 AM EDT | BioMark Diagnostics, Inc.
TempraMed Signs Definitive Five-Year Saudi Arabia Distribution Agreement for Private-Label VIVI Cap
Highlights Five-year definitive agreement with approximately US$3.8 million in potential minimum purchase commitments, beginning with a firm 10,000-unit initial purchase order. Agreement covers a private-label version of VIVI Cap™ intended for retail commercialization through the physical pharmacy network of Nahdi Medical Company, Saudi Arabia's largest pharmacy chain. TempraMed believes t
Technologies, Biotechnologies, Pharmaceutique, Santé
2026-08-25 7:00 AM EDT | TempraMed Technologies Ltd.
Theralase(R) Closes C$3.6 Million Brokered Financing
Toronto, Ontario--(Newsfile Corp. - August 24, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and viruses, is pleased to announce that it has closed its previously announced brokered private placement offering ("Offering")
Technologies, Biotechnologies, Soins de santé et hôpitaux, Pharmaceutique
2026-08-24 5:01 PM EDT | Theralase Technologies Inc.
NorthPalm Commits Entire Cybeats Position to a 12-Month Lock-Up; 60 Million Shares Representing Approximately 30% of Cybeats
Toronto, Ontario--(Newsfile Corp. - August 24, 2026) - NorthPalm Capital Corp. (CSE: NP) ("NorthPalm" or the "Company"), is pleased to announce that it has committed to a 12-month lock-up of its entire remaining position of 60,000,000 common shares of Cybeats Technologies Corp. (CSE: CYBT) ("Cybeats"), representing approximately 30% of Cybeats' outstanding shares. NorthPalm remains the largest institutional shareholder of Cybeats and is committed to maintaining a signif
Biotechnologies, Soins de santé et hôpitaux, Santé
2026-08-24 9:39 AM EDT | NorthPalm Capital Corp.
MustGrow Receives First Milestone Payment from Bayer AG
Saskatoon, Saskatchewan--(Newsfile Corp. - August 21, 2026) - MustGrow Biologics Corp. (TSXV: MGRO) (OTCQB: MGROF) (FSE: 0C0) ("MustGrow") is pleased to
Agriculture, Biotechnologies, Cannabis, Sélectionneurs de cannabis
2026-08-21 7:00 AM EDT | MustGrow Biologics Corp.
Noveris Health Sciences Announces Proposed Private Placement of Convertible Debentures for up to $500,000
Vancouver, British Columbia--(Newsfile Corp. - August 20, 2026) - Noveris Health Sciences Inc. (CSE: NVRS) (FSE: 0NF1) (OTC Pink: MYCOF) (the "Company" or "Noveris") is pleased to announce its intention to complete a non-brokered private placement of convertible debentures of the Company (the "Debentures") in an aggregate principal amount of up to $500,000, issuable in increments of $1,000 principal amount, for aggregate gross proceeds of up to $500,000 (the "Offering
2026-08-20 6:14 PM EDT | Noveris Health Sciences Inc.
iSpecimen Completes Large-Scale International Cancer Research Order; Samples Shipped Within Three Weeks
Woburn, Massachusetts--(Newsfile Corp. - August 20, 2026) - iSpecimen, (NASDAQ: ISPC) a provider of human biospecimens, recently completed an international cancer research project involving hundreds of cancer blood specimens, with the samples shipped within three weeks of receiving the purchase order. The project involved the coordination of large-scale biospecimen sourcing and fulfillment on an accelerated timeline. Through its network of healthcare and research partners, iSpecimen coo
2026-08-20 4:05 PM EDT | iSpecimen Inc.
Hemostemix Commercializes Its Vascular Dementia Clinical Trial of VesCell(TM) Under LARTA
Calgary, Alberta--(Newsfile Corp. - August 20, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is plea
Biotechnologies, Pharmaceutique, Santé
2026-08-20 9:44 AM EDT | Hemostemix Inc.
Maxwell Biosciences' Spinout SHU.ai Announces Closing of $1M Financing Round
Austin, Texas--(Newsfile Corp. - August 20, 2026) - Maxwell Biosciences, a global health technology company pioneering a new category of immune-inspired small molecules called Claromers®, December 5, 2025 incorporated its first spinout SHU.ai and June 27, 2026 announced the closing of SHU's $1 million Seed round. The round was oversubscribed and fully funded by private angel investors and led by Keiretsu Forum, "The World's Largest Angel Investor Network." The funds will support accelera
Biotechnologies, Pharmaceutique
2026-08-20 9:00 AM EDT | Maxwell Biosciences, Inc.
TempraMed Announces Extension of Maccabi Healthcare Services Agreement
Toronto, Ontario--(Newsfile Corp. - August 20, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (OTCQB: TMPTF) (FSE: 9DY) ("TempraMed" or the "Company"), a medical technology innovator focused on temperature-sensitive medication protection, is pleased to announce that Maccabi Healthcare Services ("Maccabi"), Israel's second-largest health maintenance organization ("HMO"), has exercised its option to extend its agreement with TempraMed for an additional year u
Technologies, Biotechnologies, Pharmaceutique, Santé
2026-08-20 7:00 AM EDT | TempraMed Technologies Ltd.